Submit to Special Issue Submit Abstract to Special Issue Review for Molecules Propose a Special Issue

Journal Browser

► Journal Browser

Cell-Penetrating Peptides: A Promising Tool for Drug Delivery

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 2889

Share This Special Issue

Special Issue Editors

Prof. Dr. Keykavous Parang

E-Mail Website
Guest Editor

Center For Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, USA
Interests: peptides as cell-penetrating molecular transporters; drug delivery; protein kinase inhibitors; multifunctional antivirals; anticancer agents; antibacterial agents; peptide nanomaterials

Dr. Sandeep Lohan

E-Mail Website
Guest Editor

Center for Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA, USA
Interests: cell-penetrating peptides; antimicrobial peptides; macrocyclic peptides; molecular transporters; targeted drug delivery; siRNA delivery; non-viral gene delivery

Special Issue Information

Dear Colleagues,

The clinical success of any drug molecule mainly depends on its availability at the target site. Physiochemical properties, such as low solubility and/or large molecular size, result in poor pharmacokinetic properties, which eventually hampers their therapeutic applications. Cell-penetrating peptides (CPPs) are one of the potential categories that have been investigated to be used in drug delivery. CPPs are small peptides that contain 5-40 amino acid residues and have emerged as a powerful tool to overcome the plasma membrane barrier of many mammalian cells for the intracellular or transcellular delivery of a variety of cargos, including small molecule drugs, nanoparticles, liposomes, nucleic acids, peptides, and proteins. The unique section of CPPs, also known as protein transduction domains (PTDs), facilitates the cellular uptake of large biologically active molecules with minimum toxicity. Conjugation of CPP to chemotherapeutics has shown to be a powerful approach in the selective delivery of those agents directly into cancer cells and lowering the doses of chemotherapeutic agents that generate undesired side effects and even overcoming resistance mechanisms.

The aim of this Special Issue is to provide recent findings on using linear or cyclic CPPs, including those with natural or non-natural amino acids as drug delivery tools. A major focus will also be on using CPPs with cargo drugs in the physical mixture or conjugation for diagnostic and therapeutic applications. In this Special Issue, original research articles and reviews are welcome.

We look forward to receiving your contributions.

Prof. Dr. Keykavous Parang
Dr. Sandeep Lohan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

cell-penetrating peptide
targeted drug delivery
protein delivery
small molecule delivery
mode of cell penetration

Published Papers (3 papers)

Download All Papers

Research

Jump to: Review

13 pages, 2464 KiB

Open AccessArticle

In Vitro Study of Tumor-Homing Peptide-Modified Magnetic Nanoparticles for Magnetic Hyperthermia

by Shengli Zhou, Kaname Tsutsumiuchi, Ritsuko Imai, Yukiko Miki, Anna Kondo, Hiroshi Nakagawa, Kazunori Watanabe and Takashi Ohtsuki

Molecules 2024, 29(11), 2632; https://doi.org/10.3390/molecules29112632 - 3 Jun 2024

Abstract

Cancer cells have higher heat sensitivity compared to normal cells; therefore, hyperthermia is a promising approach for cancer therapy because of its ability to selectively kill cancer cells by heating them. However, the specific and rapid heating of tumor tissues remains challenging. This study investigated the potential of magnetic nanoparticles (MNPs) modified with tumor-homing peptides (THPs), specifically PL1 and PL3, for tumor-specific magnetic hyperthermia therapy. The synthesis of THP-modified MNPs involved the attachment of PL1 and PL3 peptides to the surface of the MNPs, which facilitated enhanced tumor cell binding and internalization. Cell specificity studies revealed an increased uptake of PL1- and PL3-MNPs by tumor cells compared to unmodified MNPs, indicating their potential for targeted delivery. In vitro hyperthermia experiments demonstrated the efficacy of PL3-MNPs in inducing tumor cell death when exposed to an alternating magnetic field (AMF). Even without exposure to an AMF, an additional ferroptotic pathway was suggested to be mediated by the nanoparticles. Thus, this study suggests that THP-modified MNPs, particularly PL3-MNPs, hold promise as a targeted approach for tumor-specific magnetic hyperthermia therapy. Full article

(This article belongs to the Special Issue Cell-Penetrating Peptides: A Promising Tool for Drug Delivery)

► Show Figures

Figure 1

15 pages, 2833 KiB

Open AccessArticle

Comparing Variants of the Cell-Penetrating Peptide sC18 to Design Peptide-Drug Conjugates

by Joshua Grabeck, Tamara Lützenburg, Pia Frommelt and Ines Neundorf

Molecules 2022, 27(19), 6656; https://doi.org/10.3390/molecules27196656 - 7 Oct 2022

Cited by 1 | Viewed by 2022

Abstract

Herein, the design and synthesis of peptide-drug conjugates (PDCs) including different variants of the cell-penetrating peptide sC18 is presented. We first generated a series of novel sequence mutants of sC18 having either amino acid deletions and/or substitutions, and then tested their biological activity. The effects of histidine substituents were found to be not meaningful for sC18 uptake and cell selectivity. Moreover, building a nearly perfect amphipathic structure within a shortened sC18 derivative provided a peptide that was highly membrane-active, but also too cytotoxic. As a result, the most promising analog was sC18^ΔE, which stands out due to its higher uptake efficacy compared to parent sC18. In the last set of experiments, we let the peptides react with the cytotoxic drug doxorubicin by Thiol–Michael addition to form novel PDCs. Our results indicate that sC18^ΔE could be a more efficient drug carrier than parent sC18 for biomedical applications. However, cellular uptake using endocytosis and resulting entrapment of cargo inside vesicles is still a major critical step to overcome in CPP-containing peptide-drug development. Full article

(This article belongs to the Special Issue Cell-Penetrating Peptides: A Promising Tool for Drug Delivery)

► Show Figures

Figure 1

Review

Jump to: Research

16 pages, 997 KiB

Open AccessReview

Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA

by Jamie Leckie and Toshifumi Yokota

Molecules 2024, 29(11), 2658; https://doi.org/10.3390/molecules29112658 - 4 Jun 2024

Abstract

Spinal muscular atrophy (SMA) is a severe neuromuscular disorder that is caused by mutations in the survival motor neuron 1 (SMN1) gene, hindering the production of functional survival motor neuron (SMN) proteins. Antisense oligonucleotides (ASOs), a versatile DNA-like drug, are adept at binding to target RNA to prevent translation or promote alternative splicing. Nusinersen is an FDA-approved ASO for the treatment of SMA. It effectively promotes alternative splicing in pre-mRNA transcribed from the SMN2 gene, an analog of the SMN1 gene, to produce a greater amount of full-length SMN protein, to compensate for the loss of functional protein translated from SMN1. Despite its efficacy in ameliorating SMA symptoms, the cellular uptake of these ASOs is suboptimal, and their inability to penetrate the CNS necessitates invasive lumbar punctures. Cell-penetrating peptides (CPPs), which can be conjugated to ASOs, represent a promising approach to improve the efficiency of these treatments for SMA and have the potential to transverse the blood–brain barrier to circumvent the need for intrusive intrathecal injections and their associated adverse effects. This review provides a comprehensive analysis of ASO therapies, their application for the treatment of SMA, and the encouraging potential of CPPs as delivery systems to improve ASO uptake and overall efficiency. Full article

(This article belongs to the Special Issue Cell-Penetrating Peptides: A Promising Tool for Drug Delivery)

► Show Figures